Literature DB >> 27048397

Diminution of falsely elevated tumour markers following immunosuppression for systemic lupus erythematosus with neurological involvement.

Jonathan Bevan1, Michael Richardson1.   

Abstract

We describe the case of a patient with a long history of undifferentiated connective tissue disease who developed headache, ataxia and orofacial dyskinesia attributed to a diagnosis of systemic lupus erythematosus (SLE). Gross elevation of the concentration of several plasma tumour markers (CEA, CA-125, CA19-9, CA15-3) was detected in the absence of malignancy. These markers fell significantly within a month of starting immunosuppressive therapy alongside clinical improvement. Caution should be taken in the interpretation of plasma tumour markers in patients with connective tissue disease. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27048397      PMCID： PMC4840743          DOI： 10.1136/bcr-2016-214549

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  17 in total

1.  The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA.

Authors:  S Maestranzi; R Przemioslo; H Mitchell; R A Sherwood
Journal:  Ann Clin Biochem       Date:  1998-01       Impact factor: 2.057

2.  Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate presence of cancer.

Authors:  Samuel Bergamaschi; Edelton Morato; Maria Bazzo; Fabricio Neves; Sonia Fialho; Glaucio Castro; Adriana Zimmermann; Ivanio Pereira
Journal:  Int J Rheum Dis       Date:  2011-09-22       Impact factor: 2.454

3.  False elevation of serum CA-125 level caused by human anti-mouse antibodies.

Authors:  Roger L Bertholf; Laura Johannsen; Benrubi Guy
Journal:  Ann Clin Lab Sci       Date:  2002       Impact factor: 1.256

Review 4.  The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation.

Authors:  F G I Jennekens; L Kater
Journal:  Rheumatology (Oxford)       Date:  2002-06       Impact factor: 7.580

Review 5.  The clinical utility of the CA 19-9 tumor-associated antigen.

Authors:  W Steinberg
Journal:  Am J Gastroenterol       Date:  1990-04       Impact factor: 10.864

Review 6.  Increased plasma concentrations of tumour markers in the absence of neoplasia.

Authors:  Jaume Trapé; Xavier Filella; Montse Alsina-Donadeu; Lluïsa Juan-Pereira; Ángels Bosch-Ferrer; Raül Rigo-Bonnin
Journal:  Clin Chem Lab Med       Date:  2011-09-06       Impact factor: 3.694

7.  Rheumatoid arthritis: correlation between rheumatoid factor levels and CA-125 tumour marker elevation.

Authors:  Nicolas Tsavaris; Clio P Mavragani; Dimitrios Pikazis; Pikazis Dimitrios
Journal:  Ann Rheum Dis       Date:  2007-07       Impact factor: 19.103

8.  Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorometric assay.

Authors:  O C Boerman; M F Segers; L G Poels; P Kenemans; C M Thomas
Journal:  Clin Chem       Date:  1990-06       Impact factor: 8.327

9.  The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.

Authors:  Chee-Seng Yee; Vernon T Farewell; David A Isenberg; Bridget Griffiths; Lee-Suan Teh; Ian N Bruce; Yasmeen Ahmad; Anisur Rahman; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; Christopher Edwards; David D'Cruz; Munther A Khamashta; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2011-01-18       Impact factor: 7.580

Review 10.  Tumor markers in clinical practice: a review focusing on common solid cancers.

Authors:  Michael J Duffy
Journal:  Med Princ Pract       Date:  2012-05-15       Impact factor: 1.927
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.